TY - JOUR
T1 - Bioprinting towards Physiologically Relevant Tissue Models for Pharmaceutics
AU - Peng, Weijie
AU - Unutmaz, Derya
AU - Ozbolat, Ibrahim T.
N1 - Funding Information:
This work has been supported by National Science Foundation CMMI Awards 1349716 and 1462232, Diabetes in Action Research and Education Foundation grant #426, the Osteology Foundation grant #15-042, and the China Scholarship Council 201308360128. The authors are grateful to Monika Hospodiuk and Hemanth Gudupati for subimages in Figure 2 and Donna Sosnoski for her assistance with the typesetting of the manuscript.
Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Improving the ability to predict the efficacy and toxicity of drug candidates earlier in the drug discovery process will speed up the introduction of new drugs into clinics. 3D in vitro systems have significantly advanced the drug screening process as 3D tissue models can closely mimic native tissues and, in some cases, the physiological response to drugs. Among various in vitro systems, bioprinting is a highly promising technology possessing several advantages such as tailored microarchitecture, high-throughput capability, coculture ability, and low risk of cross-contamination. In this opinion article, we discuss the currently available tissue models in pharmaceutics along with their limitations and highlight the possibilities of bioprinting physiologically relevant tissue models, which hold great potential in drug testing, high-throughput screening, and disease modeling.
AB - Improving the ability to predict the efficacy and toxicity of drug candidates earlier in the drug discovery process will speed up the introduction of new drugs into clinics. 3D in vitro systems have significantly advanced the drug screening process as 3D tissue models can closely mimic native tissues and, in some cases, the physiological response to drugs. Among various in vitro systems, bioprinting is a highly promising technology possessing several advantages such as tailored microarchitecture, high-throughput capability, coculture ability, and low risk of cross-contamination. In this opinion article, we discuss the currently available tissue models in pharmaceutics along with their limitations and highlight the possibilities of bioprinting physiologically relevant tissue models, which hold great potential in drug testing, high-throughput screening, and disease modeling.
UR - http://www.scopus.com/inward/record.url?scp=84991237189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991237189&partnerID=8YFLogxK
U2 - 10.1016/j.tibtech.2016.05.013
DO - 10.1016/j.tibtech.2016.05.013
M3 - Review article
C2 - 27296078
AN - SCOPUS:84991237189
SN - 0167-7799
VL - 34
SP - 722
EP - 732
JO - Trends in Biotechnology
JF - Trends in Biotechnology
IS - 9
ER -